In the last trading session, 6.56 million Sangamo Therapeutics Inc (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.42. With the company’s per share price at $0.70 changed hands at -$0.27 or -27.55% during last session, the market valuation stood at $125.77M. SGMO’s last price was a discount, traded about -177.14% off its 52-week high of $1.94. The share price had its 52-week low at $0.29, which suggests the last value was 58.57% up since then. When we look at Sangamo Therapeutics Inc’s average trading volume, we note the 10-day average is 2.52 million shares, with the 3-month average coming to 2.28 million.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Instantly SGMO was in red as seen at the end of in last trading. With action -9.87%, the performance over the past five days has been red. The drop to weekly highs of 0.9782 subtracted -27.55% to the stock’s daily price. The company’s shares are showing year-to-date upside of 29.39%, with the 5-day performance at -9.87% in the red. However, in the 30-day time frame, Sangamo Therapeutics Inc (NASDAQ:SGMO) is -36.09% down. Looking at the short shares, we see there were 10.06 million shares sold at short interest cover period of 3.03 days.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Data shows that the Sangamo Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -13.27% over the past 6 months, a 8.47% in annual growth rate that is considerably lower than the industry average of 12.20%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Sangamo Therapeutics Inc will fall -275.00%, while the growth in revenue is estimated to hit 78.80% for the next quarter. Year-over-year growth is forecast to reach -74.00% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of $6.65 million. 6 analysts are of the opinion that Sangamo Therapeutics Inc’s revenue for the quarter ending Jun 2024 will be $8.24 million. The company’s revenue for the corresponding quarters a year ago was $157.96 million and $14.83 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -95.80%. The estimates for the next quarter sales put growth at -44.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.96%. The 2024 estimates are for Sangamo Therapeutics Inc earnings to increase by 63.74%.
SGMO Dividends
Sangamo Therapeutics Inc is expected to release its next quarterly earnings report between April 24 and April 29.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 10.72% of Sangamo Therapeutics Inc shares while 49.66% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 55.62%. There are 49.66% institutions holding the Sangamo Therapeutics Inc stock share, with Blackrock Inc. the top institutional holder. As of Dec 30, 2023, the company held 7.88% of the shares, roughly 14.1 million SGMO shares worth $9.91 million.
Vanguard Group Inc holds the second largest percentage of outstanding shares, with 7.04% or 12.6 million shares worth $8.86 million as of Dec 30, 2023.
Among Mutual Funds, the top two as of Dec 30, 2023 were Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund. With 8.69 million shares estimated at $6.11 million under it, the former controlled 4.86% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.39% of the shares, roughly 4.28 million shares worth around $3.01 million.
